Before you can access ASH's online program, you must agree to the following:
Last updated January 16, 2009. Please note that this site represents the latest program changes
and differs from the print version in some details.

332.O1.6 Antithrombotic Therapy - Novel Anticoagulants

Sunday, December 7, 2008: 4:30 PM-6:00 PM
3007-3009-3011 - West (Moscone Center)
Moderators:
Frederick Rickles and John A. Heit
4:30 PM
Randomized Double-Blind Comparison of Apixaban with Enoxaparin for Thromboprophylaxis after Knee Replacement: The ADVANCE-1 Trial

Michael Rud Lassen, MD1*, Alexander S Gallus, MD2*, Graham F Pineo, MD3, Gary E Raskob, PhD4 and the ADVANCE-1 Investigators5*

1Horsholm Hospital, Spine Clinic, Clinical Trials Unit, University of Copenhagen, Horsholm, Denmark
2Haematology Directorate SA Pathology, Flinders University, Adelaide, Australia
3University of Calgary, Calgary, AB, Canada
4College of Public Health, University of Oklahoma Health Sciences Center, Oklahoma City, OK
5Study sponsored by Bristol Myers Squibb/Pfizer

4:45 PM
Idrabiotaparinux, a Biotinylated Long-Acting Anticoagulant, in the Treatment of Deep Venous Thrombosis (EQUINOX Study): Safety, Efficacy, and Reversibility by Avidin

Harry Roger Buller, MD, PhD1*, Jean-Michel Destors, Clinical, Study, Director2*, Alexander S. Gallus, MD3, Martin H Prins, MD, PhD4* and Gary Edward Raskob, PhD5

1Dept of Vascular Medicine, Academic Medical Center, Amsterdam, Netherlands
2Thrombosis Therapeutic Department, Sanofi-Aventis recherche & développement, Antony Cedex, France
3SouthPath, Flinders Medical Centre, Bedford Park, SA, Australia
4Clinical Epidemiology and Medical Technology Assessment, Maastricht University Medical Center, Maastricht, Netherlands
5Univ. of OK Health Sciences Ctr., Oklahoma City, OK

5:00 PM
Randomized, Parallel Group, Multicenter, Multinational Study Evaluating Safety of DU-176b Compared with Warfarin in Subjects with Non-Valvular Atrial Fibrillation

Jeffrey I. Weitz, MD, FACP, FRCP1, Stuart J. Connolly, MD, FRCPC2*, Satoshi Kunitada3*, James Jin3* and Indravadan Patel3*

1Henderson Research Centre, Hamilton, ON, Canada
2Division of Cardiology, McMaster University, Hamilton, ON, Canada
3Daiichi Sankyo Pharma Development, Edison, NJ

5:15 PM
Randomized, Double-Blind, Multi-Dose Efficacy, Safety and Biomarker Study of the Oral Factor Xa Inhibitor DU-176b Compared with Placebo for Prevention of Venous Thromboembolism in Patients after Total Knee Arthroplasty

Takashi Fuji, MD1*, Satoru Fujita, MD2*, Shintaro Tachibana, MD3* and Yohko Kawai, MD4

1Department of Orthopaedic Surgery, Osaka Koseinenkin Hospital, Osaka, Japan
2Department of Orthopaedic Surgery, Takarazuka Daiichi Hospital, Hyogo, Japan
3Department of Orthopaedic Surgery, Toranomon Hospital, Tokyo, Japan
4Sanno Hospital, Tokyo, Japan

5:30 PM
Once-Daily Oral Rivaroxaban Compared with Subcutaneous Enoxaparin Every 12 Hours for Thromboprophylaxis after Total Knee Replacement: RECORD4

Alexander GG Turpie, MD1*, Kenneth A. Bauer, MD2, Bruce Davidson, MD3*, Michael Gent, MD4*, Louis Kwong, MD5*, Michael Rud Lassen, MD6*, Fred Cushner, MD7*, Paul Lotke, MD8*, Scott D. Berkowitz, MD, FACP9, Tiemo Joerg Bandel10*, Frank Misselwitz, MD11 and William Fisher, MD12*

1HHSC McMaster Clinic, McMaster University, Hamilton, ON, Canada
2Beth Israel Deaconess Medical Center, Boston, MA
3University of Washington School of Medicine, Seattle, WA
4Faculty of Health Sciences, McMaster University, W. Hamilton, Canada
5Harbor-UCLA Medical Center, Torrance, CA
6Spine Clinic, Clinical Trials Unit,University of Copenhagen, Horsholm Hospital, Horsholm, Denmark
7Insall Scott Kelly Center for Orthopaedics and Sports Medicine, New York, NY
8University of Pennsylvania Medical Center, Phildelphia, PA
9Bayer, West Haven, CT
10Bayer HealthCare AG, Wuppertal, Germany
11Bayer Healthcare Agency, Wuppertal, Germany
12McGill University Health Centre, Montreal, Canada

5:45 PM
A Pooled Analysis of Four Pivotal Studies of Rivaroxaban for the Prevention of Venous Thromboembolism after Orthopaedic Surgery: Effect on Symptomatic Venous Thromboembolism, Death, and Bleeding

Alexander GG Turpie, MD1*, Michael Rud Lassen, MD2*, Ajay K Kakkar, Prof., PhD3, Bengt Eriksson, MD, PhD4*, Frank Misselwitz, MD5, Tiemo Joerg Bandel, MD6*, Martin Homering7*, Torsten Westermeier, PhD6* and Michael Gent, DSc8*

1HHSC McMaster Clinic, McMaster University, Hamilton, ON, Canada
2Spine Clinic, Clinical Trials Unit,University of Copenhagen, Horsholm Hospital, Horsholm, Denmark
3Barts and The London School of Medicine, London, United Kingdom
4Sahlgrenska University Hospital / Östra, Gothenburg, Sweden
5Bayer Healthcare Agency, Wuppertal, Germany
6Bayer Healthcare AG, Wuppertal, Germany
7Bayer HealthCare AG, Wuppertal, Germany
8Faculty of Health Sciences, McMaster University, W. Hamilton, Canada

*signifies non-member of ASH